

Melanie Senior

Biopharma reporter for Nature Biotechnology, Evaluate Pharma, IN VIVO. Science strategy writer for biopharma firms

Melanie covers the science and business of biopharma for Nature Biotechnology, Evaluate Pharma and Citeline. She also supports selected pharma, biotech and market access firms with news analyses and reports.

After beginning her career at the London Financial Times, Melanie became Bureau Chief, Europe, for Elsevier Business Intelligence. She worked as a reimbursement and pricing analyst for Real Endpoints in the US and was part of EY Life Sciences' thought leadership team between 2014-2017.

Melanie holds a First class degree in Natural Sciences (biochemistry) from Cambridge University and has post-graduate qualifications in Sports Physiology & Nutrition (St Mary's University) and in International Health Technology Assessment (University of Sheffield). She is based in London, UK.